Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
28 stopped studies mapped to Polycythemia Vera and descendants · 82% state a reason
Over the 28 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05853458 | Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM…(HU-F-AIM) | Phase 4 | terminated | May 10, 2023 | Novartis Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT06290765 | Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera(PV) | Phase 4 | withdrawn | Mar 4, 2024 | PharmaEssentia | In alignment with company strategic direction. | Sponsor / business decision |
| NCT03878199 | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of… | Phase 1 / Phase 2 | terminated | Mar 18, 2019 | Ohio State University Comprehensive Cancer Center | The study was originally planned to assess four escalating DLs of ruxolitinib (upto 40 mg twice… | Enrollment / accrual |
| NCT04551066 | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With… | Phase 3 | terminated | Sep 16, 2020 | Incyte Corporation | The study was terminated due to futility. | Efficacy / futility |
| NCT04551053 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With… | Phase 3 | terminated | Sep 16, 2020 | Incyte Corporation | The study was terminated due to futility. | Efficacy / futility |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell… | Phase 2 | terminated | Nov 7, 2017 | Roswell Park Cancer Institute | Futility analysis determined closure | Efficacy / futility |
| NCT03755518 | A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary…(FREEDOM) | Phase 3 | terminated | Nov 28, 2018 | Celgene | Slow accrual. | Enrollment / accrual |
| NCT03972943 | CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential… | Early Phase 1 | terminated | Jun 4, 2019 | University of Utah | Study terminated due to lack of funding | Funding |
| NCT04896112 | A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera… | Phase 1 | withdrawn | May 21, 2021 | Lynk Pharmaceuticals Co., Ltd | sponsor decision | Sponsor / business decision |
| NCT01014546 | Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | Phase 1 | terminated | Nov 17, 2009 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT03287245 | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of… | Phase 2 | terminated | Sep 19, 2017 | Hoffmann-La Roche | The Sponsor decided to discontinue the development of idasanutlin in the polycythemia vera… | Sponsor / business decision |
| NCT02055781 | Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and…(PAC326) | Phase 3 | terminated | Feb 5, 2014 | CTI BioPharma | not stated | Not stated |
| NCT04283526 | Study of Select Combinations in Adults With Myelofibrosis | Phase 1 | withdrawn | Feb 25, 2020 | Novartis Pharmaceuticals | This study was cancelled before enrolling any patients for business related reasons. | Enrollment / accrual |
| NCT01773187 | Pacritinib Versus Best Available Therapy to Treat Myelofibrosis | Phase 3 | terminated | Jan 23, 2013 | CTI BioPharma | not stated | Not stated |
| NCT01038856 | Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera(OSI-TAR-766) | Phase 2 | terminated | Dec 24, 2009 | University of Oklahoma | The study was terminated by the sponsor | Other (stated, no rule matched) |
| NCT03121599 | 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms | N/A | terminated | Apr 20, 2017 | Hamad Medical Corporation | Delayed study materials, poor recruitment | Enrollment / accrual |
| NCT01998828 | Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential… | Phase 2 | terminated | Dec 2, 2013 | Sierra Oncology LLC - a GSK company | not stated | Not stated |
| NCT02871323 | Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential… | Phase 1 | withdrawn | Aug 18, 2016 | Northwestern University | PI decided to withdraw the study after it opened for enrollment but before any patients were… | Enrollment / accrual |
| NCT04054245 | PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera… | Phase 2 | withdrawn | Aug 13, 2019 | M.D. Anderson Cancer Center | "Company is in a process of being taken over by another pharma and the new one has different ideas… | Sponsor / business decision |
| NCT02421354 | Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia… | Phase 2 | terminated | Apr 20, 2015 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00538980 | Dasatinib in Polycythemia Vera | Phase 2 | terminated | Oct 3, 2007 | Weill Medical College of Cornell University | This study was terminated due to lack of efficacy. | Efficacy / futility |
| NCT02805868 | Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential… | Early Phase 1 | withdrawn | Jun 20, 2016 | Northwestern University | Funding | Funding |
| NCT02663648 | Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders | — | withdrawn | Jan 26, 2016 | Shandong University | No eligible patient was enrolled. | Enrollment / accrual |
| NCT00595829 | A Phase 1 Study of XL019 in Adults With Polycythemia Vera | Phase 1 | terminated | Jan 16, 2008 | Exelixis | not stated | Not stated |
| NCT01291784 | Anti-TGF-beta Therapy in Patients With Myelofibrosis | Phase 1 | terminated | Feb 8, 2011 | John Mascarenhas | Early termination when the drug was no longer made available by the pharmaceutical company due to… | Sponsor / business decision |
| NCT00940784 | Clopidogrel and Aspirin for the Treatment of Polycythemia Vera(ISCLAP) | Phase 2 | withdrawn | Jul 16, 2009 | Ronald Hoffman | Could not get drug | Other (stated, no rule matched) |
| NCT01645124 | Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)(CYTO-PV) | Phase 3 | terminated | Jul 20, 2012 | Consorzio Mario Negri Sud | Low accrual rate not allowing planned sample size leads to a futility condition | Efficacy / futility |
| NCT00522574 | A Safety Study of XL019 in Adults With Myelofibrosis | Phase 1 | terminated | Aug 29, 2007 | Exelixis | Due to emerging safety data | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 18, 2026source: clinicaltrials